Skip to main content
OpenTrials
Completed

NCT Number: NCT02835391

PerClot Compared to Usual Care in Gynaecology Procedures

This study is a post market, multi-centre, randomised study evaluating PerClot compared to usual care. PerClot is a CE marked device and is currently used as a haemostat in gynaecological surgery throughout Europe. The purpose of this study is to collect additional post market data on its use in this indication.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study is a post market, multi-centre, randomised study evaluating PerClot compared to usual care.

All subjects in this randomized study will undergo a laparoscopic or open gynecological procedure such as hysterectomy, cystectomy, myomectomy, endometrial excision or ablation. Subjects will be randomized to receive PerClot or usual care.

This research will utilize a multi-center, prospective, randomized controlled study. The study will be conducted in2 study sites in Europe. An assumed sample of 90 subjects will be enrolled to evaluate the time to haemostasis. The enrollment of subjects to receive treatment will be based upon specific inclusion and exclusion criteria. Subjects will be randomized on a 1:1 basis to receive either PerClot or usual care. Data collected from both arms will be compared.

Usual care will be at the discretion of the surgeon and may include any other haemostat or diathermy/electrocautery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥ 18 years of age
  • Subject is undergoing gynecological procedure
  • Subject is willing and able to comply with the protocol and follow up period
  • Subject is willing and able to give written informed consent

Exclusion criteria

  • • Subject with a history of pelvic or abdominal radiotherapy (within 8 weeks)
  • Subject is pregnant or actively breastfeeding
  • Subject has a ruptured ectopic pregnancy
  • Subject has a medical history of abnormal coagulopathy or bleeding
  • Subject has a sensitivity to starch or starch derived materials
  • Subject has active or potential infection at the surgical site
  • Subject is currently enrolled in another study

Treatment and study plan

PerClot

Device

Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.

Floseal, Surgicel, Surgiflo, Arista

Device

Haemostatic device for the control of bleeding

Electrocautery/Diatermy

Procedure

Procedure for the control of bleeding

Primary outcomes

  1. achievement of haemostasis (yes/no).

    Time frame: measured up to 10 minutes after application

    visual observation of cessation of bleeding

Secondary outcomes

  1. Absence of re-intervention for post-operative bleeding

    Time frame: within 30 days of initial surgery

    No return to OR for bleeding

Other outcomes

  1. Absence of proven infection

    Time frame: within 30 days of initial surgery

    No positive culture of blood results which indicate infection

  2. Absence of bleeding related adverse events

    Time frame: within 30 days of initial surgery

    No adverse events which are specifically caused by bleeding

Sponsors and collaborators

Lead sponsor

CryoLife Europa

Industry

Registry information

Official study title

A Prospective, Multi-Centre, Randomized, Safety and Effectiveness Study of PerClot Compared to Usual Care When Used During Gynaecology Procedures

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jul 18, 2016
Registry last updated
Sep 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.